Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, agitation associated with dementia due to Alzheimer’s disease, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, as well as multiple novel product candidates addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Reporting to the Associate Director, Clinical Budgets and Contracts, this role will lead CDA review and processing through execution, develop and negotiate site budgets from study start-up through close-out, and support site payments.